Novo Nordisk A/S $NVO Shares Sold by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 94.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 5,091 shares of the company’s stock after selling 95,033 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Wynn Capital LLC lifted its stake in shares of Novo Nordisk A/S by 12.6% in the 2nd quarter. Wynn Capital LLC now owns 8,605 shares of the company’s stock valued at $413,000 after purchasing an additional 960 shares during the period. Cohen Capital Management Inc. raised its position in shares of Novo Nordisk A/S by 9.7% in the second quarter. Cohen Capital Management Inc. now owns 11,312 shares of the company’s stock worth $542,000 after acquiring an additional 1,000 shares during the period. 55 North Private Wealth LLC purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $215,000. Fermata Advisors LLC grew its position in shares of Novo Nordisk A/S by 7.4% during the 2nd quarter. Fermata Advisors LLC now owns 11,833 shares of the company’s stock valued at $567,000 after acquiring an additional 817 shares during the period. Finally, Martin Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 2.6% in the 2nd quarter. Martin Capital Partners LLC now owns 120,258 shares of the company’s stock valued at $5,765,000 after purchasing an additional 3,078 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk raised its full-year sales and profit outlook for the second time this year. Management cited accelerating demand for the Wegovy pill and continued growth in obesity care, while recent coverage noted that second-quarter revenue and earnings exceeded analyst expectations. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: A Texas judge dismissed antitrust claims alleging Novo and Eli Lilly improperly restricted access to compounded GLP-1 weight-loss drugs. The ruling reduces a potential legal overhang for Novo’s obesity-drug business. Lilly and Novo Win a Key GLP-1 Antitrust Fight
• Positive Sentiment: The company declared a dividend of $0.5786 per share for investors of record August 17, payable August 25. The payout may provide some support for income-focused investors, although the reported yield in the announcement appears anomalous.
• Neutral Sentiment: CEO Mike Doustdar and CFO Karina Hertmann are emphasizing a reset in investor expectations and a more disciplined approach to growth after a difficult period. Their comments could help rebuild confidence, but they also underscore pressure to improve execution and regain momentum. Novo Nordisk CEO resets expectations for Wegovy’s explosive growth
• Neutral Sentiment: Novo appointed Omnicom as its U.S. media-buying agency of record, a move intended to strengthen marketing for its obesity portfolio but unlikely to materially affect near-term earnings. Novo Nordisk makes Omnicom agency of record for US media buying
• Negative Sentiment: Wegovy pill sales totaled about $497 million, narrowly missing forecasts. Investors remain concerned that the launch is not progressing rapidly enough to offset slowing momentum in Novo’s injectable obesity products. Novo Nordisk CEO addresses investor expectations after Wegovy pill sales miss forecasts
• Negative Sentiment: Eli Lilly’s stronger obesity-drug performance is widening the perceived competitive gap. Analysts also point to U.S. pricing pressure, patent losses, slower product development and pipeline impairments as reasons the raised outlook has not fully changed the negative narrative around Novo’s obesity business. The divide between Eli Lilly and Novo Nordisk is widening

Novo Nordisk A/S Stock Up 2.7%

NVO opened at $47.21 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $47.00 and a 200 day moving average price of $45.02. The company has a market cap of $210.77 billion, a PE ratio of 11.54, a price-to-earnings-growth ratio of 4.16 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion for the quarter. Sell-side analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be given a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 42.79%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Five analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $65.81.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.